Does Ivermectin Help Rosacea?

Topical ivermectin 1% cream is one of the most effective treatments available for the bumps and pimple-like lesions of papulopustular rosacea, the subtype that affects millions of people worldwide. It works through a dual mechanism, killing microscopic Demodex mites that live on the face while simultaneously calming inflammation in the skin. The story of how an antiparasitic drug became a frontline rosacea treatment is tied to growing evidence that those tiny mites play a bigger role in rosacea than dermatologists once thought.

Why a Parasite Drug Works on a Skin Condition

Rosacea has long been treated as a purely inflammatory condition, managed with antibiotics and anti-inflammatory creams. But research over the past two decades has shifted attention toward Demodex folliculorum, a microscopic mite that lives in hair follicles on the face. These mites exist on virtually everyone’s skin in small numbers, but people with rosacea tend to harbor far more of them. In one study of skin biopsies, the mite was present in about 80% of rosacea patients compared with 30% of controls, and having the mite substantially increased the odds of a rosacea diagnosis.¹

The connection between mite density and rosacea severity is not uniform across subtypes. Histological studies have found Demodex mites in roughly two-thirds of cases of the mildest rosacea subtype (erythematotelangiectatic, or redness-dominant rosacea), in up to nearly 100% of papulopustular cases, and in 100% of the thickened-skin forms.² This pattern helps explain why ivermectin, a drug that kills mites, works so well for the bump-and-pustule form of rosacea and less dramatically for the redness-only version.

The Two Ways Ivermectin Attacks Rosacea

Ivermectin does not just kill mites and leave the rest of the picture alone. It acts on two fronts, which is a large part of why it outperforms many older treatments.

On the antiparasitic side, ivermectin blocks chemical signaling across nerve connections in invertebrates, targeting specific chloride channels that do not exist in mammals. This causes paralysis and death in mites and other arthropods.³ In a real-world study of rosacea patients, about a third tested positive for Demodex before treatment, and every one of them tested negative after 16 weeks of topical ivermectin.⁴

On the anti-inflammatory side, ivermectin dials down several immune signals that drive rosacea symptoms. Skin treated with topical ivermectin shows reduced levels of LL-37 (a peptide that triggers inflammation and is found in excess in rosacea skin), along with drops in other inflammatory markers like TNF-α and a receptor involved in the skin’s immune alarm system.⁵ Lab studies have confirmed that ivermectin also suppresses secretion of additional inflammatory chemicals from skin cells.⁶ This dual action means ivermectin isn’t just waiting for mites to die off; it’s actively calming the redness and swelling while the mites are being eliminated.

How Ivermectin Stacks Up Against Other Topical Treatments

Most people diagnosed with papulopustular rosacea want to know which cream actually works best. Ivermectin has been tested head-to-head against the two other mainstays: metronidazole cream and azelaic acid gel.

In a large randomized trial comparing ivermectin 1% cream (applied once daily) to metronidazole 0.75% cream (applied twice daily), ivermectin reduced inflammatory lesions by about 83% at 16 weeks versus roughly 74% for metronidazole, a statistically significant gap visible as early as week three.⁷ A subanalysis of patients with severe disease showed an even wider margin: roughly 83% of those using ivermectin were rated as treatment successes at 16 weeks compared to about 63% on metronidazole.⁸

The comparison with azelaic acid is a bit more nuanced. A network meta-analysis pooling data across multiple trials found that azelaic acid 20% actually ranked highest for effectiveness among topicals, with ivermectin 1% close behind, and azelaic acid 15% and metronidazole in a comparable tier.⁹ However, a separate network meta-analysis found ivermectin significantly more likely to achieve treatment success than azelaic acid 15% gel and metronidazole at 12 weeks, with a notably lower risk of side effects compared to azelaic acid.¹⁰ The takeaway from these comparisons is that ivermectin sits at or near the top of available topical options and tends to be better tolerated, which matters for a condition that often requires months of continuous use.

Tolerability and Side Effects

One of ivermectin cream’s practical advantages is its side-effect profile. Rosacea-prone skin is famously reactive and sensitive; many patients have tried treatments they had to abandon because of burning, stinging, or dryness. In 40-week extension studies comparing ivermectin 1% cream to azelaic acid 15% gel, ivermectin caused fewer treatment-related side effects, and no patients using ivermectin stopped the study due to an adverse reaction.¹¹ The once-daily application schedule also helps with compliance compared to twice-daily regimens.

An initial flare during the first week or two of treatment can sometimes happen. Dermatologists attribute this to the die-off of Demodex mites, which can temporarily release their contents into the follicle and provoke a reaction. This typically settles on its own and is not a reason to stop treatment, though it can be alarming if you are not expecting it.

What Happens When You Stop

Rosacea is a chronic condition, and one of the most frustrating realities is that stopping treatment often means the bumps come back. The relapse picture with ivermectin is better than with metronidazole, but it is far from perfect. In a 36-week follow-up after successful treatment, patients initially treated with ivermectin had a longer median time before their first relapse (about 115 days versus 85 days for metronidazole), and a somewhat lower overall relapse rate.¹²

A separate study tracking patients for 48 weeks after they stopped ivermectin found that about 45% relapsed, with a median time to relapse of roughly 140 days. That means about 55% maintained their clear skin throughout the full follow-up period without additional treatment.¹³ Many dermatologists now recommend a maintenance strategy, applying ivermectin less frequently (a few times per week rather than daily) after the initial clearing phase to keep mite populations suppressed and inflammation low.

Quality of Life Improvements

The numbers on bump reduction and treatment success rates are useful, but what rosacea patients really care about is whether their face looks and feels better in everyday life. Rosacea has an outsized impact on self-esteem, social interactions, and even career confidence, particularly because it affects the most visible part of the body. A meta-analysis pooling quality-of-life data from clinical trials found that patients using ivermectin 1% cream were significantly more likely to report better quality of life at both 16 weeks and 52 weeks compared to those on other topicals.¹⁴ The sustained improvement at a year is particularly noteworthy, because it suggests the benefits hold up over the kind of timeframe that reflects real life rather than a controlled trial window.

Combining Ivermectin with Other Treatments

For moderate-to-severe papulopustular rosacea, topical ivermectin alone may not be enough. Dermatologists frequently pair it with other therapies to attack the disease from multiple angles. The most studied combination is ivermectin cream plus oral doxycycline at an anti-inflammatory dose (40 mg modified-release, which is lower than the antibiotic dose). The rationale is that doxycycline hits different inflammatory pathways than ivermectin does, so the two together cover more of the underlying disease process.¹⁵

For patients whose main complaints include both bumps and persistent background redness, researchers have also tested combining ivermectin with brimonidine, a topical vasoconstrictor that specifically targets facial flushing. An eight-week study found the combination effective at improving both erythema and inflammatory lesions in mild-to-moderate cases.¹⁶ This makes practical sense because ivermectin addresses bumps and pustules far better than it addresses persistent redness, and brimonidine does the opposite.

Oral Ivermectin for Rosacea

Most of the clinical evidence centers on topical ivermectin cream, which is the FDA-approved formulation for rosacea (sold under the brand name Soolantra in the U.S.). But oral ivermectin has generated interest as well, particularly for patients with severe or treatment-resistant disease. A case report described a patient with papulopustular rosacea who had failed retinoids, topical immunomodulators, and repeated courses of doxycycline. A single weight-based oral dose of ivermectin produced significant improvement within two weeks, and the patient remained in complete remission for six months without any topical treatment.¹⁷

A clinical study tracking oral ivermectin treatment in rosacea patients found significant improvement, consistent with a decrease in Demodex mite counts after treatment.¹⁸ Oral ivermectin is not considered first-line treatment for rosacea and is used off-label, but it can be a useful option when topical therapy alone has not been enough or when very high mite counts suggest a heavy infestation driving the condition.

What Ivermectin Does Not Fix

It is worth being clear about what ivermectin cannot do. Rosacea is not one disease but a spectrum of related problems, and ivermectin’s strengths are concentrated in specific areas.

Persistent facial redness (the hallmark of subtype 1 rosacea) does not respond dramatically to ivermectin. While some mild improvement in erythema can occur as inflammation settles, the dilated blood vessels that cause chronic flushing are a structural problem that ivermectin does not reverse. Treatments like laser and intense pulsed light therapy, or topical vasoconstrictors like brimonidine, are better suited for this aspect of the disease.

Ivermectin also does not appear to correct the bacterial imbalance found on rosacea skin. A recent study systematically profiled patients’ skin before and after 30 days of topical ivermectin and found that while mite density dropped markedly in nearly 90% of patients and inflammatory gene activity normalized significantly, the bacterial dysbiosis on the skin surface remained unchanged.¹⁹ This finding is interesting because it suggests that ivermectin’s clinical benefits come primarily from killing mites and quieting the immune response, not from reshaping the skin’s microbial community. Bacterial dysbiosis may be a separate contributor to rosacea that requires additional or different interventions.

Ivermectin and Ocular Rosacea

Up to half of rosacea patients develop eye symptoms, including irritation, redness, and a gritty sensation often diagnosed as blepharitis. These symptoms are also linked to Demodex mites, which colonize eyelash follicles. Applying ivermectin cream to the facial skin (not directly to the eyes) has shown encouraging results for ocular symptoms as well. In a study of rosacea patients with eye involvement, 16 weeks of daily topical ivermectin 1% cream led to significant improvements in blepharitis, conjunctival redness, corneal staining, and tear film stability, with no side effects reported.²⁰ The likely explanation is that reducing the mite population on the surrounding facial skin decreases the reservoir of mites that migrate to the eyelid margins.

Cost and Access Considerations

One practical barrier to ivermectin cream is its cost. As a relatively newer branded treatment, Soolantra has typically been more expensive than generic metronidazole. A cost-effectiveness analysis in the U.S. found that ivermectin 1% cream was more costly than metronidazole but provided enough additional clinical benefit to be considered cost-effective, while it actually saved money compared to azelaic acid 15% gel over a three-year horizon because of its greater effectiveness and the reduced need for treatment switches.²¹ Generic versions of topical ivermectin have begun to reach some markets, which is improving affordability. Some patients and compounding pharmacies have also experimented with diluting veterinary ivermectin paste for topical facial use, but this approach comes with real risks of incorrect concentration and contamination and is not recommended by dermatologists.

From a Golf Course in Japan to Your Medicine Cabinet

Ivermectin’s path to becoming a rosacea treatment is one of the more improbable stories in modern medicine. In 1971, Japanese microbiologist Satoshi Ōmura collected a soil sample from a golf course in Kawana, Japan. The bacterial culture isolated from that sample eventually yielded avermectin, a compound refined into ivermectin, which proved more than 25 times more potent than existing antiparasitic drugs.²² It launched as a veterinary treatment in 1981, then transformed human health through mass distribution programs for river blindness in sub-Saharan Africa. Ōmura and his collaborator William Campbell won the Nobel Prize in Physiology or Medicine in 2015 for the discovery. The leap from livestock dewormer to rosacea cream came decades later, as researchers connected the dots between Demodex mites and inflammatory skin disease. It is a reminder that drug repurposing sometimes takes the scenic route: a soil bacterium from a Japanese golf course, refined into a veterinary antiparasitic, turned into a Nobel Prize-winning treatment for tropical disease, and finally repackaged as a once-daily face cream for a condition that affects millions in wealthy countries.